December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunovant, Inc. - Common Stock (NQ:IMVT)

26.53 -0.96 (-3.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immunovant, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
Immunovant Inc. (NASDAQ: IMVT) Records 52-Week High Tuesday Morning
Via Investor Brand Network
News headline image
Why Is Autoimmune Disease-Focused Immunovant Stock Trading Higher Today? ↗
Immunovant Inc (NASDAQ: IMVT), a unit of Roivant Sciences Ltd (NASDAQ: ROIV), announced that subcutaneously administered doses of IMVT-1402 produced dose-dependent reductions in Immunoglobulin G (IgG)... 
Via Benzinga
News headline image
These 2 Biotech Stocks Are Bucking a Down Market Tuesday ↗
Stock index futures pointed to a lower open on Wall Street Tuesday morning. 
Via The Motley Fool
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Where Immunovant Stands With Analysts ↗
 
Via Benzinga
News headline image
What 11 Analyst Ratings Have To Say About Immunovant ↗
 
Via Benzinga
News headline image
9 Analysts Have This to Say About Immunovant ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Pre-market stock movers are among the biggest topics worth checking out on Tuesday and we have the latest news for investors! 
Via InvestorPlace
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
If You Invested $1000 In Vivek Ramaswamy-Founded Roivant When He Declared Presidential Bid, Here's How Much You'd Have Now ↗
Roivant stock has outperformed the broader market and the biotech sector this year, mirroring the rise in the fortunes of its founder Vivek Ramaswamy. 
Via Benzinga
News headline image
Immunovant's FcRn Strategy Gains Momentum: Analysts View ADHERE Study as De-Risking Factor for CIDP Clinical Development ↗
Monday, Argenx SE (NASDAQ: ARGX) reported topline results from the ADHERE study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with chronic inflammatory demyelinating... 
Via Benzinga
News headline image
HC Wainwright & Co. Maintains Buy Rating for Immunovant: Here's What You Need To Know ↗
 
Via Benzinga
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 5/23
Via Investor Brand Network
News headline image
Analyst Expectations for Immunovant's Future ↗
 
Via Benzinga
News headline image
Recap: Immunovant Q4 Earnings ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start off the trading week with a breakdown of all the biggest pre-market stock movers worth watching on Monday! 
Via InvestorPlace
News headline image
Activision Blizzard, Argenx And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
U.S. stock futures traded mixed this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023 ↗
 
Via Benzinga
News headline image
Analyst Expectations for Immunovant's Future ↗
 
Via Benzinga
News headline image
7 Analysts Have This to Say About Immunovant ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2023 ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023 ↗
 
Via Benzinga
Immunovant Inc. (NASDAQ: IMVT) is a Stock Spotlight on 3/24
Via Investor Brand Network
News headline image
Analyst Boosts Immunovant Price Target After Updated Pipeline Realignment ↗
 
Via Benzinga
News headline image
Immunovant Could Potentially Be An M&A Target, Writes Analyst ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023 ↗
 
Via Benzinga
News headline image
Analyst Expectations for Immunovant's Future ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023 ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.